심장 스캔 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the heart scan market size is expected to increase from USD 16.89 billion in 2025 to USD 18.01 billion in 2026 and reach USD 25.11 billion by 2031, growing at a CAGR of 6.88% over 2026-2031.

This report is Segmented by Modality (Echocardiography, and More), Application (Coronary Artery Disease Diagnosis, and More), End User (Hospitals and Clinics, and More), Technology (2D Imaging, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Market Forecasts are Provided in Terms of Value (USD).

Global Heart Scan Market Trends and Insights

Rising Cardiovascular Disease Burden and Earlier Non-Invasive Assessment

Population aging, high blood pressure, dietary risks, and metabolic conditions are expected to increase the cardiovascular disease burden through 2050. More than 75% of cardiovascular disease deaths occur in low- and middle-income countries, where diagnostic imaging capacity remains limited. This gap supports demand in the heart scan market for systems that are lower cost, portable, and connected to clinical networks. It also favors suppliers with tiered portfolios rather than a single premium product line. Earlier non-invasive assessment widened the role of CCTA and echocardiography before invasive procedures are considered. Ambulatory and point-of-care settings can extend imaging access when equipment, staffing, and reimbursement support their use.

AI-Enabled Workflow Automation and Quantitative Interpretation

AI tools are changing image acquisition, measurement, and interpretation in the heart scan market. A 2025 scientific statement found that successful AI deployment in cardiac CT and MRI currently favors institutions with established information technology resources. This means that the near-term benefits of automation are likely to be concentrated in better-resourced care settings. Siemens Healthineers introduced the ACUSON Origin in 2025 with more than 500 AI-supported measurements, real-time cardiac view recognition, and automated Doppler placement. A 2025 clinical review reported that AI-enabled point-of-care echocardiography can reduce operator dependence and improve acquisition consistency. The heart scan market, therefore, includes both native AI embedded by equipment suppliers and cross-vendor software offered by specialized providers.

High Capital, Maintenance, and Total Cost of Ownership

Advanced imaging systems, including 3-Tesla cardiac MRI and photon-counting CT platforms, remain beyond the purchasing capacity of many public health systems. The cost extends beyond acquisition to service contracts, specialist training, contrast agents, and radiopharmaceutical supply chains. These expenses can lead providers to defer purchases, choose lower-specification equipment, or retain systems beyond their intended replacement cycle. The result is a widening diagnostic capability gap between high-income and lower-income settings. Portable ultrasound can lower some equipment costs, but it does not eliminate the requirements for trained personnel and clinical networks. The heart scan market needs purpose-built, lower-cost offerings and financing approaches that fit public-sector procurement conditions.

Other drivers and restraints analyzed in the detailed report include:

1. Reimbursement Recognition of CCTA and Cardiac AI Analysis
2. Contrast-Free and Lower-Resource Cardiac MRI Workflows
3. Shortage of Cardiac Imaging Specialists and Sonographers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Echocardiography held 31.35% of the heart scan market in 2025, supported by its lower cost, broad availability, real-time imaging, and established reimbursement. Transthoracic echocardiography, or TTE, accounts for most procedure volume within the modality. Intracardiac echocardiography is gaining relevance as structural heart interventions increase. Cardiac CT includes CCTA, calcium scoring, and photon-counting CT applications. Nuclear cardiac imaging also remains relevant for perfusion assessment. Cardiac angiography and fluoroscopy primarily serve interventional rather than purely diagnostic use.

Cardiac magnetic resonance imaging is projected to grow at a 10.48% CAGR from 2026 to 2031, making it the fastest-growing modality in the heart scan industry. Its use is supported by evidence in cardiomyopathy characterization, myocardial viability assessment, and planning for structural heart procedures. The shift from 1.5-Tesla to 3-Tesla systems is increasing clinical interest in higher-resolution cardiac MRI. In February 2026, Inova became the first health system to implement GE HealthCare's SIGNA Sprint Elite 1 system for high-resolution cardiac imaging. New MRI platforms must continue to meet MRI safety and quality-management requirements in major markets.

Coronary artery disease diagnosis represented 44.29% of the heart scan market size in 2025, making it the largest application. Its position reflects the large global burden of ischemic heart disease, which affected 254.28 million people. CCTA is becoming a more important non-invasive coronary assessment method, particularly after the 2025 reimbursement change. Heart failure, structural heart disease, congenital heart disease, and arrhythmia assessment represent additional applications. These applications use different modality preferences, including cardiac MRI for cardiomyopathy and nuclear imaging for perfusion assessment. U.S. FDA clearance pathways and European CE marking under EU MDR 2017/745 continue to influence how new applications reach clinicians.

Valvular heart disease evaluation is forecast to grow at a 12.60% CAGR through 2031. Growth is tied to transcatheter aortic valve replacement and transcatheter mitral valve replacement, which require imaging before, during, and after procedures. In March 2026, Philips received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, a real-time guidance system for mitral transcatheter edge-to-edge repair developed with Edwards Lifesciences. AI ECG screening tools may create additional referrals for echocardiography and cardiac CT. EchoNext achieved 77% structural heart disease detection accuracy using a standard 12-lead ECG, compared with 64% for unaided cardiologists. This creates a potential screening-to-imaging pathway that was less developed previously.

Complete Report Scope:

• By Modality
  • Echocardiography
    • Transthoracic Echocardiography
    • Transesophageal Echocardiography
    • Stress Echocardiography
    • Intracardiac Echocardiography
    • Fetal Echocardiography
  • Cardiac Computed Tomography
    • Coronary CT Angiography
    • Calcium Scoring CT
    • Cardiac CT for Structural Heart Planning
    • Photon-Counting Cardiac CT
  • Cardiac Magnetic Resonance Imaging
    • Closed Cardiac MRI Systems
    • Open Cardiac MRI Systems
    • 1.5-Tesla and 3-Tesla Cardiac MRI
    • Very High-Field Cardiac MRI
  • Nuclear Cardiac Imaging
    • SPECT Myocardial Perfusion Imaging
    • PET Myocardial Perfusion Imaging
    • Hybrid Nuclear Cardiac Imaging
  • Cardiac Angiography and Fluoroscopy
    • Coronary Angiography
    • Digital Subtraction Angiography
    • Intravascular Ultrasound-Guided Imaging
    • Optical Coherence Tomography-Guided Imaging
• By Application
  • Coronary Artery Disease Diagnosis
  • Heart Failure Assessment and Monitoring
  • Structural Heart Disease Assessment
  • Valvular Heart Disease Evaluation
  • Congenital Heart Disease Evaluation
  • Arrhythmia and Electrophysiology Assessment
  • Other Applications
• By End User
  • Hospitals and Clinics
  • Diagnostic Imaging Centers
  • Specialty Cardiac Centers
  • Ambulatory Surgical Centers
  • Other End Users
• By Technology
  • 2D Imaging
  • 3D and 4D Imaging
  • Doppler and Contrast-Enhanced Imaging
  • AI-Enabled Imaging Solutions
  • Other Technologies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.70% of the heart scan market in 2025. The United States accounted for much of the regional volume because of its institutional density, early technology adoption, and active reimbursement reform. The 2025 CCTA payment increase and new AI-supported imaging tools are supporting procurement activity in the region. GE HealthCare launched Flyrcado, a unit-dose PET myocardial perfusion imaging agent, in March 2025 with CMS pass-through status effective April 1, 2025. Canada and Mexico remain secondary regional markets with different reimbursement and procurement cycles.

Europe is the second-largest geography in the heart scan market. Its mature technology base and EU MDR 2017/745 requirements influence the order of product launches across modalities. Germany, the United Kingdom, and France support regional demand through cardiology networks, academic medical centers, and specialist care. The July 2026 VNE study across the United Kingdom and Chinese hospital centers showed how clinical partnerships can help standardize imaging protocols where gadolinium access differs. Italy and Spain have more price-sensitive procurement patterns. Other European countries remain at different stages of cardiac imaging infrastructure development.

Asia-Pacific is forecast to grow at a 10.60% CAGR from 2026 to 2031, making it the fastest-growing geographic area. Domestic Chinese manufacturers are expanding their presence in high-end imaging, supported by public hospital procurement and rising demand for advanced diagnostic capacity. India is expanding cardiac imaging capacity through private multi-specialty hospital investment, while cardiac MRI remains limited by scanner access and post-processing costs. Japan and South Korea are innovation and manufacturing centers, and their regulatory agencies set important quality expectations. The Middle East and Africa, and South America, provide smaller growth opportunities through cardiac-center investment and public healthcare expansion. Philips signed a May 2026 memorandum with the Asian Society of Cardiovascular Imaging to support education and AI collaboration across Asia-Pacific.

1. Abbott Laboratories
2. Agfa-Gevaert
3. Bayer
4. Boston Scientific
5. Bracco Imaging S.p.A.
6. Canon
7. Circle Cardiovascular Imaging Inc.
8. Esaote S.p.A.
9. FUJIFILM
10. GE HealthCare Technologies Inc.
11. Guerbet S.A.
12. Koninklijke Philips
13. Medis Medical Imaging Systems
14. Medtronic
15. Samsung Group
16. Shanghai United Imaging Healthcare Co., Ltd.
17. Mindray
18. Shimadzu
19. Siemens Healthineers
20. Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Cardiovascular Disease Burden and Diagnostic Demand
  • 4.2.2 Shift Toward Non-Invasive and Earlier Cardiac Assessment
  • 4.2.3 AI-Enabled Workflow Automation and Quantitative Interpretation
  • 4.2.4 Expansion of Ambulatory and Point-of-Care Cardiac Imaging
  • 4.2.5 Reimbursement Recognition of CCTA and Cardiac AI Analysis
  • 4.2.6 Contrast-Free and Lower-Resource Cardiac MRI Workflows
• 4.3 Market Restraints
  • 4.3.1 High Capital, Maintenance, and Total Cost of Ownership
  • 4.3.2 Shortage of Cardiac Imaging Specialists and Sonographers
  • 4.3.3 Cross-Vendor Data Heterogeneity and AI Generalizability Risk
  • 4.3.4 Uneven Reimbursement and Limited Rural Imaging Capacity
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Modality
  • 5.1.1 Echocardiography
    • 5.1.1.1 Transthoracic Echocardiography
    • 5.1.1.2 Transesophageal Echocardiography
    • 5.1.1.3 Stress Echocardiography
    • 5.1.1.4 Intracardiac Echocardiography
    • 5.1.1.5 Fetal Echocardiography
  • 5.1.2 Cardiac Computed Tomography
    • 5.1.2.1 Coronary CT Angiography
    • 5.1.2.2 Calcium Scoring CT
    • 5.1.2.3 Cardiac CT for Structural Heart Planning
    • 5.1.2.4 Photon-Counting Cardiac CT
  • 5.1.3 Cardiac Magnetic Resonance Imaging
    • 5.1.3.1 Closed Cardiac MRI Systems
    • 5.1.3.2 Open Cardiac MRI Systems
    • 5.1.3.3 1.5-Tesla and 3-Tesla Cardiac MRI
    • 5.1.3.4 Very High-Field Cardiac MRI
  • 5.1.4 Nuclear Cardiac Imaging
    • 5.1.4.1 SPECT Myocardial Perfusion Imaging
    • 5.1.4.2 PET Myocardial Perfusion Imaging
    • 5.1.4.3 Hybrid Nuclear Cardiac Imaging
  • 5.1.5 Cardiac Angiography and Fluoroscopy
    • 5.1.5.1 Coronary Angiography
    • 5.1.5.2 Digital Subtraction Angiography
    • 5.1.5.3 Intravascular Ultrasound-Guided Imaging
    • 5.1.5.4 Optical Coherence Tomography-Guided Imaging
• 5.2 By Application
  • 5.2.1 Coronary Artery Disease Diagnosis
  • 5.2.2 Heart Failure Assessment and Monitoring
  • 5.2.3 Structural Heart Disease Assessment
  • 5.2.4 Valvular Heart Disease Evaluation
  • 5.2.5 Congenital Heart Disease Evaluation
  • 5.2.6 Arrhythmia and Electrophysiology Assessment
  • 5.2.7 Other Applications
• 5.3 By End User
  • 5.3.1 Hospitals and Clinics
  • 5.3.2 Diagnostic Imaging Centers
  • 5.3.3 Specialty Cardiac Centers
  • 5.3.4 Ambulatory Surgical Centers
  • 5.3.5 Other End Users
• 5.4 By Technology
  • 5.4.1 2D Imaging
  • 5.4.2 3D and 4D Imaging
  • 5.4.3 Doppler and Contrast-Enhanced Imaging
  • 5.4.4 AI-Enabled Imaging Solutions
  • 5.4.5 Other Technologies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Agfa-Gevaert N.V.
  • 6.3.3 Bayer AG
  • 6.3.4 Boston Scientific Corporation
  • 6.3.5 Bracco Imaging S.p.A.
  • 6.3.6 Canon Medical Systems Corporation
  • 6.3.7 Circle Cardiovascular Imaging Inc.
  • 6.3.8 Esaote S.p.A.
  • 6.3.9 FUJIFILM Holdings Corporation
  • 6.3.10 GE HealthCare Technologies Inc.
  • 6.3.11 Guerbet S.A.
  • 6.3.12 Koninklijke Philips N.V.
  • 6.3.13 Medis Medical Imaging Systems B.V.
  • 6.3.14 Medtronic plc
  • 6.3.15 Samsung Medison Co., Ltd.
  • 6.3.16 Shanghai United Imaging Healthcare Co., Ltd.
  • 6.3.17 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 6.3.18 Shimadzu Corporation
  • 6.3.19 Siemens Healthineers AG
  • 6.3.20 Terumo Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment